When analyzing the biomolecular changes that ensued with rituximab treatment, it was shown that intraperitoneal injections of rituximab (250 mg/kg/week) downregulated the expression of NFκB, TNFα, and IL-6, as well as the GM-CSF signaling pathway, in a murine collagen-induced RA model [193]. This evidence concerns the gene IL6 and rheumatoid arthritis.